Patents by Inventor Steven L. Gonias

Steven L. Gonias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF PROMOTING CNS NEURONAL REPAIR BY INHIBITING LRP-1
    Publication number: 20210284708
    Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).
    Type: Application
    Filed: November 5, 2020
    Publication date: September 16, 2021
    Applicant: The J. David Gladstone Institutes
    Inventors: Steven L. Gonias, Travis Stiles, Alban Gaultier, Wendy M. Campana, Katerina Akassoglou
  • Methods of promoting CNS neuronal repair by inhibiting LRP-1
    Patent number: 10829536
    Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: November 10, 2020
    Assignee: The Regents of the University of California
    Inventors: Steven L. Gonias, Travis Stiles, Alban Gaultier, Wendy M. Campana, Katerina Akassoglou
  • METHODS OF PROMOTING CNS NEURONAL REPAIR BY INHIBITING LRP-1
    Publication number: 20190284254
    Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).
    Type: Application
    Filed: June 22, 2016
    Publication date: September 19, 2019
    Applicant: The J. David Gladstone Institutes
    Inventors: Steven L. Gonias, Travis Stiles, Alban Gaultier, Wendy M. Campana, Katerina Akassoglou
  • Methods of promoting CNS neuronal repair by inhibiting LRP-1
    Patent number: 9376481
    Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: June 28, 2016
    Assignees: The Regents of the University of California, J. David Gladsone Institutes
    Inventors: Steven L. Gonias, Travis Stiles, Alban Gaultier, Wendy M. Campana, Katerina Akassoglou
  • METHODS OF PROMOTING CNS NEURONAL REPAIR BY INHIBITING LRP-1
    Publication number: 20140161807
    Abstract: This invention provides methods for promoting and/or restoring neurite outgrowth and neuronal regeneration by contacting an injured neuron with an inhibitor of low density lipoprotein receptor-related protein-1 (LRP-1).
    Type: Application
    Filed: April 26, 2012
    Publication date: June 12, 2014
    Applicant: The Regents of The University of California
    Inventors: Steven L. Gonias, Travis Stiles, Alban Gaultier, Wendy M. Campana, Katerina Akassoglou
  • Transforming growth factor-&bgr; binding site
    Patent number: 6329500
    Abstract: The present invention relates to a composition and method for inhibiting TGF-&bgr; activity. The composition comprises a TGF-&bgr; neutralizing peptide derived from &agr;2-macroglobulin that binds to TGF-&bgr; and inhibits TGF-&bgr; activity.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: December 11, 2001
    Assignee: University of Virginia Patent Foundation
    Inventors: Donna J. Webb, Steven L. Gonias
  • Chemically modified a-macroglobulins, methods of making, and methods of using the same in anti-cytokine therapy
    Patent number: 5902787
    Abstract: Chemically modified .alpha.-macroglobulin is conformationally locked by cross-linking .alpha..sub.2 M with a bi-functional peptide crosslinker, and then modified with methylamine, to provide conformational intermediates with limited conformational change. These modified compounds have a high binding affinity for inflammatory cytokines including TNF-.alpha. and IL-1.beta.. When administered in vivo, the modified .alpha..sub.2 M (MAC) protects against development of septic shock, and is an effective treatment aid in treating mammals with established septic shock.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: May 11, 1999
    Assignee: The University of Virginia Patent Foundation
    Inventors: Steven L. Gonias, Donna J. Webb